Explaining drug spending trends: Does perception match reality?

Health Affairs

Volumn 19, Issue 2, 2000, Pages 231-239

  Dubois, Robert W ^a   Chawla, Anita J ^b   Neslusan, Cheryl A ^a,b   Smith, Mark W ^a,b   Wade, Sally ^a  

^a Protocare Sciences   (United States)

^b MEDSTAT GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC DISEASE; DRUG COST; DRUG UTILIZATION; ECONOMICS; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INSURANCE; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

CHRONIC DISEASE; DRUG COSTS; DRUG UTILIZATION; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE CLAIM REPORTING; MANAGED CARE PROGRAMS; UNITED STATES; UNITED STATES CENTERS FOR MEDICARE AND MEDICAID SERVICES;

EID: 0342709673     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.19.2.231     Document Type: Article

References (18)

1. Health Care Financing Administration, Office of the Actuary, www.hcfa.gov/stats/NHE-Proj/proj1998/tables/nhe65-08.txt (10 November 1999).
2. "Drug Spending Rose 84 Percent from 1993 to 1998," BNA's Health Care Policy Report (19 July 1999): 1185.
3. "Rising Prescription Drug Prices to Boost Health Premiums," BNA's Health Care Policy Report (27 September 1999): 1532.
4. C. Copeland, Prescription Drugs: Issues of Costs, Coverage, and Quality, EBRI Issue Brief no. 208 (Washington: Employee Benefit Research Institute, 1999); Prescription Drugs: Cost and Coverage Trends (Washington: Health Insurance Association of America, 1999); Barents Group LLC., Factors Affecting the Growth of Prescription Drug Expenditures (Washington: NIHCM Foundation, July 1999); and F. Teitelbaum et al., Drug Trend Report, 1998 (St. Louis: Express Scripts, 1999).
5. C. Copeland, Prescription Drugs: Issues of Costs, Coverage, and Quality, EBRI Issue Brief no. 208 (Washington: Employee Benefit Research Institute, 1999); Prescription Drugs: Cost and Coverage Trends (Washington: Health Insurance Association of America, 1999); Barents Group LLC., Factors Affecting the Growth of Prescription Drug Expenditures (Washington: NIHCM Foundation, July 1999); and F. Teitelbaum et al., Drug Trend Report, 1998 (St. Louis: Express Scripts, 1999).
6. C. Copeland, Prescription Drugs: Issues of Costs, Coverage, and Quality, EBRI Issue Brief no. 208 (Washington: Employee Benefit Research Institute, 1999); Prescription Drugs: Cost and Coverage Trends (Washington: Health Insurance Association of America, 1999); Barents Group LLC., Factors Affecting the Growth of Prescription Drug Expenditures (Washington: NIHCM Foundation, July 1999); and F. Teitelbaum et al., Drug Trend Report, 1998 (St. Louis: Express Scripts, 1999).
7. C. Copeland, Prescription Drugs: Issues of Costs, Coverage, and Quality, EBRI Issue Brief no. 208 (Washington: Employee Benefit Research Institute, 1999); Prescription Drugs: Cost and Coverage Trends (Washington: Health Insurance Association of America, 1999); Barents Group LLC., Factors Affecting the Growth of Prescription Drug Expenditures (Washington: NIHCM Foundation, July 1999); and F. Teitelbaum et al., Drug Trend Report, 1998 (St. Louis: Express Scripts, 1999).
8. Barents Group, Factors Affecting the Growth; and Teitelbaum et al., Drug Trend Report,1998.
9. Barents Group, Factors Affecting the Growth; and Teitelbaum et al., Drug Trend Report,1998.
10. To express spending growth as a sum of individual factors, a logarithmic transformation was applied to linearize the equation. Exhibit 2 shows the linearized growth rate for each factor. The total growth rate for each drug category is then the sum of the linearized growth rates for that category. Exhibit 1 depicts the sum of price and volume factors.
11. T. Pedersen et al., "Cholesterol Lowering and the Use of Healthcare Resources: Results in Scandinavian Simvastatin Survival Study," Circulation 93, no. 10 (1996): 1796-1802; M. Noyes et al., "Estrogen Therapy during Menopause and the Treatment of Osteoporosis," Primary Care 17, no. 3 (1990): 647-666; R. Sitruk-Ware, "Estrogen Therapy during Menopause: Practical Treatment Recommendations," Drugs 39, no. 2 (1990): 203-217; F. Grofstein et al., "The Epidemiology of Coronary Heart Disease and Estrogen Replacement in Postmenopausal Women," Progress in Cardiovascular Discase 38, no. 3 (1995): 199-210; and S. Gapstur, M. Morrow, and T. Sellers, "Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology," Journal of the American Medical Association 281, no. 22 (1999): 2091-2097
12. T. Pedersen et al., "Cholesterol Lowering and the Use of Healthcare Resources: Results in Scandinavian Simvastatin Survival Study," Circulation 93, no. 10 (1996): 1796-1802; M. Noyes et al., "Estrogen Therapy during Menopause and the Treatment of Osteoporosis," Primary Care 17, no. 3 (1990): 647-666; R. Sitruk-Ware, "Estrogen Therapy during Menopause: Practical Treatment Recommendations," Drugs 39, no. 2 (1990): 203-217; F. Grofstein et al., "The Epidemiology of Coronary Heart Disease and Estrogen Replacement in Postmenopausal Women," Progress in Cardiovascular Discase 38, no. 3 (1995): 199-210; and S. Gapstur, M. Morrow, and T. Sellers, "Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology," Journal of the American Medical Association 281, no. 22 (1999): 2091-2097
13. T. Pedersen et al., "Cholesterol Lowering and the Use of Healthcare Resources: Results in Scandinavian Simvastatin Survival Study," Circulation 93, no. 10 (1996): 1796-1802; M. Noyes et al., "Estrogen Therapy during Menopause and the Treatment of Osteoporosis," Primary Care 17, no. 3 (1990): 647-666; R. Sitruk-Ware, "Estrogen Therapy during Menopause: Practical Treatment Recommendations," Drugs 39, no. 2 (1990): 203-217; F. Grofstein et al., "The Epidemiology of Coronary Heart Disease and Estrogen Replacement in Postmenopausal Women," Progress in Cardiovascular Discase 38, no. 3 (1995): 199-210; and S. Gapstur, M. Morrow, and T. Sellers, "Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology," Journal of the American Medical Association 281, no. 22 (1999): 2091-2097
14. T. Pedersen et al., "Cholesterol Lowering and the Use of Healthcare Resources: Results in Scandinavian Simvastatin Survival Study," Circulation 93, no. 10 (1996): 1796-1802; M. Noyes et al., "Estrogen Therapy during Menopause and the Treatment of Osteoporosis," Primary Care 17, no. 3 (1990): 647-666; R. Sitruk-Ware, "Estrogen Therapy during Menopause: Practical Treatment Recommendations," Drugs 39, no. 2 (1990): 203-217; F. Grofstein et al., "The Epidemiology of Coronary Heart Disease and Estrogen Replacement in Postmenopausal Women," Progress in Cardiovascular Discase 38, no. 3 (1995): 199-210; and S. Gapstur, M. Morrow, and T. Sellers, "Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology," Journal of the American Medical Association 281, no. 22 (1999): 2091-2097
15. T. Pedersen et al., "Cholesterol Lowering and the Use of Healthcare Resources: Results in Scandinavian Simvastatin Survival Study," Circulation 93, no. 10 (1996): 1796-1802; M. Noyes et al., "Estrogen Therapy during Menopause and the Treatment of Osteoporosis," Primary Care 17, no. 3 (1990): 647-666; R. Sitruk-Ware, "Estrogen Therapy during Menopause: Practical Treatment Recommendations," Drugs 39, no. 2 (1990): 203-217; F. Grofstein et al., "The Epidemiology of Coronary Heart Disease and Estrogen Replacement in Postmenopausal Women," Progress in Cardiovascular Discase 38, no. 3 (1995): 199-210; and S. Gapstur, M. Morrow, and T. Sellers, "Hormone Replacement Therapy and Risk of Breast Cancer with a Favorable Histology," Journal of the American Medical Association 281, no. 22 (1999): 2091-2097
16. E. McFadden and I. Gilbert, "Asthma," New England Journal of Medicine 327, no. 27 (1992): 1928-1937.
17. National Asthma Education and Prevention Program Expert Panel Report II. Guidelines for the Diagnosis and Management of Asthma, Pub. no. 97-4051 (Bethesda, Md.: National Institutes of Health, 1997).
18. Diabetes Control and Complications Trial Research Group, "The Effect of Complications in Insulin-Dependent and Diabetes Mellitus," New England Journal of Medicine 329, no. 14 (1993): 977-986.